

MEDICAL UROLOGY FOR THE PRIMARY CARE PROVIDER

Supplement 3 to Volume 74, May 2007

Co-Editors

MATT T. ROSENBERG, MD
Mid-Michigan Health Centers

MILTON M. LAKIN, MD*
Cleveland Clinic

Associate Editor

DAVID R. STASKIN, MD*
New York Presbyterian Hospital
Weill Medical College of Cornell University

From the editors: The recognition of urologic disease is a primary care issue, whether we've known it or not	S5
Matt T. Rosenberg, MD, and Milton M. Lakin, MD	
Screening for urologic malignancies in primary care: Pros, cons, and recommendations	S6
Andrew J. Stephenson, MD; Louis Kuritzky, MD; and Steven C. Campbell, MD, PhD	
Benign prostatic hyperplasia: When to 'watch and wait,' when and how to treat	S15
Albert Levy, MD, and George P. Samraj, MD	
Overactive bladder: Recognition requires vigilance for symptoms	S21
Matt T. Rosenberg, MD; Diane K. Newman, RNC, MSN, CRNP; Christopher T. Tallman, BS; and Shari A. Page, CFNP	
Erectile dysfunction: A sentinel marker for cardiovascular disease in primary care	S30
Martin M. Miner, MD, and Louis Kuritzky, MD	
Evolving issues in male hypogonadism: Evaluation, management, and related comorbidities	S38
Martin M. Miner, MD, and Richard Sadovsky, MD	
Identifying and treating premature ejaculation: Importance of the sexual history	S47
Richard E. Payne, MD, and Richard Sadovsky, MD	
Interstitial cystitis/painful bladder syndrome: Symptom recognition is key to early identification, treatment	S54
Matt T. Rosenberg, MD; Diane K. Newman, RNC, MSN, CRNP; and Shari A. Page, CFNP	
Prostatitis: Infection, neuromuscular disorder, or pain syndrome? Proper patient classification is key	S63
Jeannette Potts, MD, and Richard E. Payne, MD	

This supplement was supported by educational grants from Ortho Women's Health & Urology, Schering Corporation, GlaxoSmithKline, Sanofi-Aventis, and ESPRIT Pharma.

* **Milton M. Lakin, MD**, has received consulting fees and honoraria from Pfizer and Eli Lilly/ICOS for consulting, teaching/speaking, and advisory board membership. He also reported having stock ownership interest in Pfizer and Eli Lilly. **David R. Staskin, MD**, has received honoraria from ESPRIT Pharma, Novartis, Pfizer, Ortho-McNeil, Watson Pharmaceuticals, and Astellas Pharma for teaching/speaking. Financial conflict-of-interest disclosures for all authors, including supplement co-editor Matt T. Rosenberg, appear within each author's respective article(s).

Copyright © 2007 The Cleveland Clinic Foundation. All rights reserved.
The statements and opinions expressed in this supplement to the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of the Cleveland Clinic Foundation or its Board of Trustees. They do not necessarily represent formal practice guidelines in effect at Cleveland Clinic.
The *Cleveland Clinic Journal of Medicine* (ISSN 0891-1150) is published 12 times yearly by the Cleveland Clinic Foundation.
Subscription rates: U.S. and possessions: personal \$108; institutional \$134; single

copy/back issue \$20. Foreign: \$134; single copy/back issue \$20. Institutional (multiple-reader rate) applies to libraries, schools, hospitals, and federal, commercial, and private organizations. Individual subscriptions must be in the names of and paid by individuals.
Postmaster address changes: *Cleveland Clinic Journal of Medicine*, NA32, 9500 Euclid Avenue, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): (216) 444-2661 (phone); (216) 444-9385 (fax); ccjm@ccf.org (e-mail); www.ccjm.org (Web).
Printed in USA.

